Person · CIK 1758247

Elizabeth M Anderson

Director at Revolution Medicines, Biomarin Pharmaceutical and INSMED

Source: Forms 3, 4, 5 and 144 on SEC EDGAR

Sold on Form 4$5.4M

Noticed on Form 144$5.9M

Bought on Form 4$0

Companies3

Holdings now

As reported after the latest Form 3, 4 or 5 at each company.

How these figures work

Options and RSUs are from the latest filing that lists them; earlier grants may also be held. Holdings can be out of date when a person stops filing.

Company	Security	Held	Shares or units	As of
Revolution Medicines RVMD	Common Stock	Directly	4,333	Sep 22, 2026 · Filing · EDGAR
Revolution Medicines RVMD	Common Stock	See footnote	15,000	Sep 22, 2026 · Filing · EDGAR
Revolution Medicines RVMD	Stock Option (Right to Buy) exercise $1.12, expires Apr 19, 2028, into Common Stock	Directly	1,095	Sep 22, 2026 · Filing · EDGAR
Biomarin Pharmaceutical BMRN	Common Stock	Directly	41,940	Jun 2, 2026 · Filing · EDGAR
INSMED INSM	Common Stock	Directly	62,034	May 13, 2026 · Filing · EDGAR

Sold and noticed by quarter

Sold (Form 4) Noticed (Form 144) Bought (Form 4)

Quarterly totals as a table

Quarter	Sold (Form 4)	Noticed (Form 144)
Q3 2026	$2M	$2.9M
Q4 2025	$3M	$3M
Q4 2020	$425K	Not machine-readable

Form 144 notices went onto EDGAR as structured data on April 13, 2023. Earlier notices were filed on paper and cannot be read here, so those quarters show no noticed amount.

Planned sales (Form 144) and the sales that followed

Each Form 144 notice of a planned sale, grouped by broker and 10b5-1 plan, with the Form 4 sales we matched to it.

How we match

A Form 144 is a notice of a planned sale by an affiliate. SEC Tracker matches each notice to Form 4 sales by the same person at the same company within 90 days of the notice, up to the shares noticed. The match is our inference, not something either filing states.

Notice date	Noticed	Planned sale	Outcome	Links
Revolution Medicines RVMD · Morgan Stanley Smith Barney · 10b5-1 plan adopted Jun 23, 2026 · 1 notice
Sep 22, 2026	15,080 · ~$2.9M	Sep 22, 2026	Partly sold Sold 10,143 in 5 sales, Sep 22 to Sep 22 · $2M likely match Form 4	Filing · EDGAR
INSMED INSM · Fidelity Brokerage Services · No 10b5-1 plan stated · 2 notices
Nov 24, 2025	5,000 · ~$1M	Nov 24, 2025	Sold as noticed Sold 5,000 at $204.58 on Nov 24 · $1M Form 4	Filing · EDGAR
Nov 13, 2025	10,000 · ~$1.9M	Nov 13, 2025	Sold as noticed Sold 10,000 at $195.87 on Nov 14 · $2M Form 4	Filing · EDGAR
Sales without a matching Form 144 · 3 sales No matching Form 144 found. Not every sale needs one: small sales and sales by people who are not affiliates are exempt.
—	—	—	Notice not machine-readable Revolution Medicines (RVMD): Sold 4,780 at $45.00 on Oct 15, 2020 · $215K (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable Revolution Medicines (RVMD): Sold 220 at $45.00 on Oct 13, 2020 · $10K (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable Revolution Medicines (RVMD): Sold 5,000 at $40.00 on Oct 6, 2020 · $200K (10b5-1 plan)	Filing · EDGAR

Every transaction, by company

Each Form 3, 4 and 5 transaction in plain words, newest first.

How these figures work

Values are shares times the price each filing states; grants, exercises and gifts usually state no price. Held after is what the filing reports was held once the transaction was done, directly or through the named holder.

Revolution Medicines RVMD Director · filings 2020 to 2026 · sold $2.4M · $2.9M noticed on Form 144

Date	Transaction	Shares	Price	Value	Held after	Source
Sep 22, 2026	Option or RSU exercised or converted	+5,070	$1.12	$6K	14,476 direct	Filing · EDGAR
Sep 22, 2026	Sale under a 10b5-1 plan	−910	$191.85	$175K	13,566 direct	Filing · EDGAR
Sep 22, 2026	Sale under a 10b5-1 plan	−4,985	$192.54	$960K	8,581 direct	Filing · EDGAR
Sep 22, 2026	Sale under a 10b5-1 plan	−2,648	$193.44	$512K	5,933 direct	Filing · EDGAR
Sep 22, 2026	Sale under a 10b5-1 plan	−1,500	$194.59	$292K	4,433 direct	Filing · EDGAR
Sep 22, 2026	Sale under a 10b5-1 plan	−100	$195.15	$20K	4,333 direct	Filing · EDGAR
Sep 22, 2026	Option or RSU exercised or converted Stock Option (Right to Buy)	−5,070			1,095 direct	Filing · EDGAR
Jun 18, 2026	Grant or award from the company	+1,191			9,406 direct	Filing · EDGAR
Jun 18, 2026	Grant or award from the company Stock Option (Right to Buy)	+3,127			3,127 direct	Filing · EDGAR
Mar 4, 2026	Gift	−15,000			8,215 direct	Filing · EDGAR
Mar 4, 2026	Gift	+15,000			15,000 See footnote	Filing · EDGAR
Jun 26, 2025	Grant or award from the company	+3,142			23,215 direct	Filing · EDGAR
Jun 26, 2025	Grant or award from the company Stock Option (Right to Buy)	+11,574			11,574 direct	Filing · EDGAR
Jun 20, 2024	Grant or award from the company	+4,248			20,073 direct	Filing · EDGAR
Jun 20, 2024	Grant or award from the company Stock Option (Right to Buy)	+15,955			15,955 direct	Filing · EDGAR
Jun 8, 2023	Grant or award from the company	+5,200			15,825 direct	Filing · EDGAR
Jun 8, 2023	Grant or award from the company Stock Option (Right to Buy)	+18,400			18,400 direct	Filing · EDGAR
Jun 16, 2022	Grant or award from the company	+5,200			10,625 direct	Filing · EDGAR
Jun 16, 2022	Grant or award from the company Stock Option (Right to Buy)	+18,400			18,400 direct	Filing · EDGAR
Jun 22, 2021	Grant or award from the company	+3,617			5,425 direct	Filing · EDGAR
Jun 22, 2021	Grant or award from the company Stock Option (Right to Buy)	+12,659			12,659 direct	Filing · EDGAR
Oct 15, 2020	Sale under a 10b5-1 plan	−4,780	$45.00	$215K	26,990 See footnote	Filing · EDGAR
Oct 13, 2020	Sale under a 10b5-1 plan	−220	$45.00	$10K	31,770 See footnote	Filing · EDGAR
Oct 6, 2020	Sale under a 10b5-1 plan	−5,000	$40.00	$200K	31,990 See footnote	Filing · EDGAR
Jun 17, 2020	Grant or award from the company	+1,808			1,808 direct	Filing · EDGAR
Jun 17, 2020	Grant or award from the company Stock Option (Right to Buy)	+6,329			6,329 direct	Filing · EDGAR

Biomarin Pharmaceutical BMRN Director · filings 2019 to 2026

Date	Transaction	Shares	Held after	Source
Jun 2, 2026	Grant or award from the company	+7,490	41,940 direct	Filing · EDGAR
May 20, 2025	Grant or award from the company	+6,650	34,450 direct	Filing · EDGAR
May 21, 2024	Grant or award from the company	+4,720	27,800 direct	Filing · EDGAR
May 23, 2023	Grant or award from the company	+4,190	23,080 direct	Filing · EDGAR
May 24, 2022	Grant or award from the company	+4,980	18,890 direct	Filing · EDGAR
May 25, 2021	Grant or award from the company	+5,120	13,910 direct	Filing · EDGAR
May 27, 2020	Grant or award from the company	+4,300	8,790 direct	Filing · EDGAR
Jul 9, 2019	Grant or award from the company	+4,490	4,490 direct	Filing · EDGAR

INSMED INSM Director · filings 2018 to 2026 · sold $3M · $3M noticed on Form 144

Date	Transaction	Shares	Price	Value	Held after	Source
May 13, 2026	Grant or award from the company	+3,305			62,034 direct	Filing · EDGAR
Nov 24, 2025	Open-market or private sale	−5,000	$204.58	$1M	58,729 direct	Filing · EDGAR
Nov 14, 2025	Open-market or private sale	−10,000	$195.87	$2M	63,729 direct	Filing · EDGAR
May 15, 2025	Grant or award from the company	+5,058			73,729 direct	Filing · EDGAR
May 13, 2024	Grant or award from the company	+13,162			68,671 direct	Filing · EDGAR
May 11, 2023	Grant or award from the company	+13,192			55,509 direct	Filing · EDGAR
May 11, 2022	Grant or award from the company	+14,645			42,317 direct	Filing · EDGAR
May 12, 2021	Grant or award from the company	+7,558			27,672 direct	Filing · EDGAR
May 12, 2020	Grant or award from the company	+8,097			20,114 direct	Filing · EDGAR
May 15, 2019	Grant or award from the company	+6,899			12,017 direct	Filing · EDGAR
Nov 6, 2018	Grant or award from the company	+5,118			5,118 direct	Filing · EDGAR

All 37 Forms 3, 4, 5 and 144

Filed	Form	Company	Links
Sep 24, 2026	Form 4	Revolution Medicines RVMD	Filing · EDGAR
Sep 22, 2026	Form 144	Revolution Medicines RVMD	Filing · EDGAR
Jun 23, 2026	Form 4	Revolution Medicines RVMD	Filing · EDGAR
Jun 4, 2026	Form 4	Biomarin Pharmaceutical BMRN	Filing · EDGAR
May 15, 2026	Form 4	INSMED INSM	Filing · EDGAR
Mar 6, 2026	Form 4	Revolution Medicines RVMD	Filing · EDGAR
Nov 26, 2025	Form 4	INSMED INSM	Filing · EDGAR
Nov 24, 2025	Form 144	INSMED INSM	Filing · EDGAR
Nov 18, 2025	Form 4	INSMED INSM	Filing · EDGAR
Nov 13, 2025	Form 144	INSMED INSM	Filing · EDGAR
Jun 30, 2025	Form 4	Revolution Medicines RVMD	Filing · EDGAR
May 22, 2025	Form 4	Biomarin Pharmaceutical BMRN	Filing · EDGAR
May 19, 2025	Form 4	INSMED INSM	Filing · EDGAR
Jun 28, 2024	Form 4/A	Revolution Medicines RVMD	Filing · EDGAR
Jun 24, 2024	Form 4	Revolution Medicines RVMD	Filing · EDGAR
May 23, 2024	Form 4	Biomarin Pharmaceutical BMRN	Filing · EDGAR
May 15, 2024	Form 4	INSMED INSM	Filing · EDGAR
Jun 12, 2023	Form 4	Revolution Medicines RVMD	Filing · EDGAR
May 24, 2023	Form 4	Biomarin Pharmaceutical BMRN	Filing · EDGAR
May 15, 2023	Form 4	INSMED INSM	Filing · EDGAR
Jun 17, 2022	Form 4	Revolution Medicines RVMD	Filing · EDGAR
May 26, 2022	Form 4	Biomarin Pharmaceutical BMRN	Filing · EDGAR
May 13, 2022	Form 4	INSMED INSM	Filing · EDGAR
Jun 24, 2021	Form 4	Revolution Medicines RVMD	Filing · EDGAR
May 27, 2021	Form 4	Biomarin Pharmaceutical BMRN	Filing · EDGAR
May 14, 2021	Form 4	INSMED INSM	Filing · EDGAR
Oct 15, 2020	Form 4	Revolution Medicines RVMD	Filing · EDGAR
Oct 8, 2020	Form 4	Revolution Medicines RVMD	Filing · EDGAR
Jun 19, 2020	Form 4	Revolution Medicines RVMD	Filing · EDGAR
May 29, 2020	Form 4	Biomarin Pharmaceutical BMRN	Filing · EDGAR
May 14, 2020	Form 4	INSMED INSM	Filing · EDGAR
Feb 12, 2020	Form 3	Revolution Medicines RVMD	Filing · EDGAR
Jul 11, 2019	Form 4	Biomarin Pharmaceutical BMRN	Filing · EDGAR
Jul 11, 2019	Form 3	Biomarin Pharmaceutical BMRN	Filing · EDGAR
May 16, 2019	Form 4	INSMED INSM	Filing · EDGAR
Nov 8, 2018	Form 4	INSMED INSM	Filing · EDGAR
Nov 8, 2018	Form 3	INSMED INSM	Filing · EDGAR

Every figure is as filed with the SEC on Forms 3, 4, 5 and 144. Holdings are the amounts reported after each person's latest filing at each company and can be out of date. Matching a Form 144 notice to Form 4 sales is SEC Tracker's inference from owner, company, dates and share counts, not something the filings state. Not investment advice. Not affiliated with the U.S. SEC.